2D High-Density Multi-Electrode Array Electrophysiology Platform

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

RFQ_CBER-2026-135968

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

6640

Additional Details
Set Aside

NONE

Place of Performance

-

SourceSAM
Documents2
The U.S. Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a combined synopsis/solicitation for the procurement of a 2D High-Density Multi-Electrode Array (MEA) Electrophysiology Platform. This opportunity, managed by the FDA’s Office of Acquisitions and Grants Services (OAGS), is intended to equip the agency with advanced laboratory instrumentation to support its scientific and regulatory mission. The scope of this procurement encompasses the delivery of a complete MEA electrophysiology platform, including all necessary hardware, software, accessories, initial consumables, installation, system verification, calibration, and training. Additionally, the contract will provide a two-year warranty from the date of final Government acceptance, with three one-year option periods for preventative maintenance and repair services. The platform is expected to enable high-density, two-dimensional electrophysiological measurements, supporting FDA research and analysis activities. This solicitation is issued as a Request for Quotation (RFQ) for commercial products and services and is being conducted on an unrestricted basis, with no set-aside for small businesses or other socioeconomic categories. The procurement is classified under NAICS Code 334516 (Analytical Laboratory Instrument Manufacturing) and Product Service Code 6640 (Laboratory Equipment and Supplies). The award will be made on a Lowest Price Technically Acceptable (LPTA) basis, with technical acceptability evaluated strictly against the minimum requirements detailed in the solicitation and attached requirements document. Offerors must ensure their quotations meet all mandatory criteria; failure to do so will result in disqualification from award consideration. Key requirements for offerors include submission of comprehensive technical documentation demonstrating compliance with the solicitation specifications, completed technical compliance information, pricing for both the base requirement and all option periods, warranty details, delivery lead time, country of origin for all offered items, Unique Entity Identifier (UEI), and confirmation of active registration in SAM.gov. The solicitation is subject to the Trade Agreements Act, requiring offerors to provide the country of origin for all end products and complete all relevant representations and certifications. The FDA will not extend the solicitation closing date or time, and no further questions will be addressed beyond the clarification provided in the latest amendment. All solicitation documents, amendments, and responses to questions will be posted on SAM.gov, and offerors are responsible for monitoring the site for updates. The primary point of contact for this procurement is Iris Johnson ([email protected], 301-796-3353), with L. Maria Finan ([email protected], 240-402-5712) as the secondary contact. Quotations are due by September 23, 2026, at 10:00 AM Eastern Time. The notice remains active and can be accessed via SAM.gov at https://sam.gov/opp/eaf1f29ee2c7418aab29419c1356d3c3/view. Contractors considering this opportunity should ensure their capabilities align with the technical and service requirements outlined, and be prepared to deliver a turnkey electrophysiology platform with robust support and maintenance options over the contract lifecycle.